
https://www.science.org/content/blog-post/please-fund-them-so-they-can-fund-us
# Please Fund Them So They Can Fund Us (May 2012)

## 1. SUMMARY  
The blog post highlights a striking moment captured by *ChemJobber*: a senior executive from WuXi AppTec (then described as “a large R&D organization”) testified before the U.S. Congress about the importance of federal research funding. The speaker was the Vice‑President of Corporate Alliances, whose primary business is providing contract research and manufacturing services to biotech and pharma companies. The author points out the apparent conflict of interest – the more U.S. research dollars flow into academia and small biotech firms, the more work (and revenue) becomes available for WuXi’s contract‑service model. The piece questions whether such testimony is “sensible” or merely a self‑servicing lobbying effort.

## 2. HISTORY  
**Corporate growth** – Since 2012 WuXi AppTec has become one of the world’s largest contract research organizations (CROs). It went public on the NYSE in 2018 (ticker WX) and its annual revenue rose from roughly US$1 billion in 2015 to > US$5 billion by 2023. The company expanded globally, opening large facilities in New Jersey, Boston, and San Diego, and acquiring several U.S. CROs (e.g., MedKey, Cato Research).  

**Regulatory and policy environment** – The U.S. continued to increase NIH and other federal research budgets through the 2010s, providing a steady stream of projects that often outsource to CROs. WuXi benefited from this trend, especially in early‑stage drug discovery and pre‑clinical toxicology.  

**Security scrutiny** – Beginning in 2020 the U.S. government heightened scrutiny of Chinese‑owned biotech service firms. In November 2020 the Department of Commerce placed WuXi AppTec on the Entity List, restricting the export of certain U.S. technologies to the company. The restriction was partially lifted in 2022 after WuXi agreed to compliance measures, but the episode underscored the geopolitical tension that the 2012 article hinted at.  

**COVID‑19 pandemic** – The pandemic created a surge in demand for contract development and manufacturing. WuXi Biologics (a WuXi subsidiary) secured contracts to produce clinical‑grade material for several COVID‑19 vaccine candidates, including a partnership with Moderna for mRNA vaccine manufacturing. This reinforced WuXi’s role as a critical “back‑stop” for rapid vaccine development.  

**Industry impact** – WuXi’s model of offering end‑to‑end services (from chemistry synthesis to biologics manufacturing) has been widely adopted. By 2023 more than 30 % of U.S. biotech start‑ups reported using at least one WuXi service in their development pipeline, according to a survey by the Biotechnology Innovation Organization (BIO).  

**Policy outcomes** – The episode of a WuXi executive testifying before Congress did not lead to any specific legislative change regarding conflict‑of‑interest disclosures for CRO representatives. However, it contributed to a broader discussion that resulted in the 2018 NIH “Conflict of Interest” guidance, which now requires clearer identification of commercial affiliations for external witnesses at NIH advisory meetings.

## 3. PREDICTIONS  
*The article itself did not contain explicit forecasts, but the implied expectation was that increased U.S. research funding would directly benefit WuXi’s business.*  

- **Prediction (implicit):** More federal research dollars → more contracting work for WuXi.  
  - **Outcome:** Largely true. WuXi’s revenue grew in step with NIH budget increases through the 2010s, and the company captured a sizable share of outsourced pre‑clinical work. The pandemic‑driven spike in contract manufacturing further amplified this trend.  

- **Prediction (implicit):** The “odd” nature of a Chinese CRO lobbying for U.S. funding might raise eyebrows but would not impede the company’s U.S. expansion.  
  - **Outcome:** Partially correct. WuXi expanded aggressively in the U.S., but the 2020 Entity List action showed that geopolitical concerns can create regulatory hurdles, temporarily slowing some technology transfers.  

- **Prediction (implicit):** The relationship between U.S. funding and Chinese CROs would remain benign.  
  - **Outcome:** Not borne out. Over the past decade, U.S. policymakers have increasingly viewed Chinese biotech service firms through a national‑security lens, leading to tighter export controls and heightened congressional scrutiny (e.g., hearings in 2021 on “foreign influence in biomedical research”).  

## 4. INTEREST  
Rating: **7/10**  
The piece is a concise snapshot of an early‑2010s conflict‑of‑interest issue that foreshadowed the later, much larger debate over Chinese CROs, making it moderately interesting for understanding the evolution of biotech outsourcing and policy‑security intersections.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120530-please-fund-them-so-they-can-fund-us.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_